The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
about
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Modern therapeutic concepts of early breast cancer.Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.Biology of breast cancer in young women.Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsProteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer.A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinomaDenoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyFOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations.Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG OncologFactors that predict recurrence later than 5 years after initial treatment in operable breast cancer.From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersMulti-gene classifiers for prediction of recurrence in breast cancer patients.A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.Indications for prognostic gene expression profiling in early breast cancer.The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.Biomarker assessment and molecular testing for prognostication in breast cancer.Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast.Clinical utility of gene-expression signatures in early stage breast cancer.Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.Targeted adjuvant therapy in breast cancer.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.
P2860
Q28077637-F3D32462-6546-4195-90BA-2274672E6730Q28079118-282D40E5-6904-4552-8DE6-B991F4660F72Q28085062-218F141C-A6DB-4334-A0E1-69E384D2B3A2Q33684843-E649F1EA-3E28-4BC5-AA16-DC226A517266Q33684849-04C60526-8B27-43A9-A8FE-82DF1D6B0896Q33827057-83EC58E5-0E5B-44B1-9129-72D6FA216958Q34042627-CE7FCE34-13F9-49E4-A149-5C534B7DF295Q34657656-17639360-7341-465B-A0E3-8BE2B3F93CC1Q35000798-33E7C9CF-3CEE-465A-BB3C-76EC2E3A4D29Q35008290-A09F7E8B-91F5-43F2-953E-75ACFC9101F3Q35313220-1DEEB2C5-57CB-47B0-81AD-B9FDEFC7862CQ35341492-F942281E-88E1-4DCE-8E94-6DD6A017C779Q35446364-5CC2CCE3-8A23-4020-BD95-12C4B065D751Q35475576-87ECE5B2-87A7-4B78-A663-CADB8CCE1E7DQ36070063-D7994514-44D3-4EC9-AF8C-C248593D6E99Q36322870-2B1A6BBA-588F-4A68-8AE7-94A0F602AAFFQ36356139-C1A7FB04-B438-418B-A5EB-9E646C767755Q36379148-A9A67631-E2D8-49DD-B513-BE655B67A09AQ36678505-5EED1401-0086-4DC3-9E0E-6D1B4E6EF45FQ36746291-5A023F7C-7A12-4890-AFAF-51E6977883B0Q36801189-0D915FC7-E9B2-4FC1-8E93-55313FC9A25BQ37169337-11B418C6-A8DC-4757-8EEB-E46BF5ED8AACQ37199625-9577C656-F9FB-4CCB-BB0B-AD39C5A0288AQ37214217-D00B603D-2F33-4B70-B924-06FF39E7262EQ37591446-F5DA3337-62DB-44AF-BAE6-707D221D2D75Q37690351-B84FAFDB-4615-490B-9E1C-181FF575D3B3Q38362985-19B2BE6C-9764-41DA-9A6D-8AB614A558BEQ38374561-9B77FF89-CCB9-4B74-83CF-75B20E5F8363Q38451798-1DAE166A-C587-4482-AEC9-718C0823CAB2Q38510960-836AA5E2-9217-4FA5-BBB1-D58BE472A81CQ38547729-DC4B4F72-B81E-4270-8E5A-8D5ABBED9F4EQ38551397-9094231F-2FF4-4151-A211-B5ACDFC36D86Q38584379-635DED10-55AC-48DF-82E3-0069FF9E0C0BQ38676979-314C44CB-59BF-4E6D-AC93-DF863337AC3AQ38696790-9F360F14-CDD2-47F6-B8FE-0A71F675F71DQ38702293-E6199521-E465-4BE0-B1C5-F5E0E45D2D68Q38754717-993CF8A4-7E9B-419D-B620-3CFE295D1A36Q38933874-0F4AC706-A2BC-4959-919C-41DE1F871E7DQ38980703-525F36B8-1597-4BDF-A0A3-65AC0967A886Q39187437-548027ED-4D09-4A0F-B4A9-7B1DED9550D4
P2860
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The EndoPredict score provides ...... /HER2- breast cancer patients.
@en
The EndoPredict score provides ...... /HER2- breast cancer patients.
@nl
type
label
The EndoPredict score provides ...... /HER2- breast cancer patients.
@en
The EndoPredict score provides ...... /HER2- breast cancer patients.
@nl
prefLabel
The EndoPredict score provides ...... /HER2- breast cancer patients.
@en
The EndoPredict score provides ...... /HER2- breast cancer patients.
@nl
P2093
P2860
P356
P1476
The EndoPredict score provides ...... +/HER2- breast cancer patients
@en
P2093
Austrian Breast and Colorectal Cancer Study Group (ABCSG)
C F Singer
P2860
P2888
P304
P356
10.1038/BJC.2013.671
P407
P577
2013-10-24T00:00:00Z